Eli Lilly to Acquire Calytrix Bio for Up to $1.5 Billion
Eli Lilly has agreed to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash. The deal, announced November 16, 2026, aims to expand Lilly’s portfolio of treatments for rare blood cancers. The agreement includes an upfront payment and additional payments tied to clinical and regulatory milestones. However, the companies have not disclosed the initial payment or expected closing date.
The acquisition centers on Calytrix’s experimental antibody treatment for essential thrombocythemia and myelofibrosis. These rare blood disorders cause the bone marrow to produce excessive abnormal blood cells. Calytrix is developing a targeted therapy designed to address disease-causing mutations rather than primarily managing symptoms. However, the treatment remains in preclinical development and has not demonstrated effectiveness in human trials.
The transaction supports Lilly’s strategy to diversify beyond its blockbuster diabetes and weight-loss medications. It also strengthens the pharmaceutical company’s presence in hematology, where its portfolio already includes the FDA-approved blood cancer treatment Jaypirca. Founded in 2025, Calytrix received backing from J.P. Morgan Life Sciences Private Capital, Westlake BioPartners, and Avoro Ventures. Lilly’s acquisition adds another experimental treatment to its expanding drug development pipeline.
Why it matters
The acquisition could strengthen Lilly's long-term drug pipeline and reduce its dependence on weight-loss medicines. However, clinical development risks remain significant, making future milestone payments uncertain.


